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doi:10.1016/j.kjms.2011.03.007Abstract There is now increasing evidence from the experimental and clinical setting that
therapeutic hypercapnia from intentionally inspired carbon dioxide (CO2) or lower tidal volume
might be a beneficial adjunct to the strategies of mechanical ventilation in critical illness.
Although previous reports indicate that CO2 exerts a beneficial effect in the lungs, the pulmo-
nary vascular response to hypercapnia under various conditions remains to be clarified. The
purpose of the present study is to characterize the pulmonary vascular response to CO2 under
the different conditions of pulmonary hypertension secondary to increased pulmonary blood
flow and secondary to hypoxic pulmonary vasoconstriction. Isolated rat lung (nZ 32) was used
to study (1) the vasoactive action of 5% CO2 in either N2 (hypoxic-hypercapnia) or air (nor-
moxic-hypercapnia) at different pulmonary arterial pressure levels induced by graded speed
of perfusion flow and (2) the role of nitric oxide (NO) in mediating the pulmonary vascular
response to hypercapnia, hypoxia, and flow-associated pulmonary hypertension. The results
indicated that inhaled CO2 reversed pulmonary hypertension induced by hypoxia but not by
flow alteration. Endogenous NO attenuates hypoxic pulmonary vasoconstriction but does nott of Internal Medicine, Kaohsiung Medical University Hospital, #100 Shih-Chuan 1st Road, Kaohsiung
tw (M.-S. Huang).
vier Taiwan LLC. All rights reserved.
Effect of inhaled CO2 on pulmonary hypertension 337augment the CO2-induced vasodilatation. Acute change in blood flow does not alter the endog-
enous NO production.
Copyright ª 2011, Elsevier Taiwan LLC. All rights reserved.Introduction
There have been contradictory reports indicating that
carbon dioxide (CO2) may constrict, dilate, or have no
action on the pulmonary vessels. Respiratory alkalosis
(hypocapnia) produced by mechanical hyperventilation is
a therapeutic strategy for persistent pulmonary hyperten-
sion in infants. Previous studies have indicated that respi-
ratory alkalosis improves oxygenation and decreases the
mean pulmonary arterial pressure (PAP) when the arterial
pH is greater than 7.55 and the PaCO2 is less than 22 mmHg
[1]. On the other hand, permissive hypercapnia with a small
tidal volume has been adapted to avoid ventilator-induced
lung injury in patients with lung injury or acute respiratory
distress syndrome. Such “protective” ventilator strategies
minimize lung stretch and patient mortality and often lead
to an elevation in PaCO2 [2e4].
There is evidence that high CO2 tension with elevated
hydrogen ion concentration (low pH) in the blood increases
the extracellular Ca2þ influx and accounts for the vaso-
constrictory property of CO2 in pulmonary circulation [5,6].
Nonetheless, CO2 also plays a vasodilator role under the
condition of high vascular tone induced by drugs or hypoxia,
and such a vasodilatory effect is related to the concentra-
tion of inhaled CO2, not to the blood pH value [7e11]. More
recently, the potential beneficial effects of therapeutic
hypercapnia as a result of direct improvements in gas
exchange, anti-inflammatory events, and attenuation of
ischemia-reperfusion, endotoxin, and ventilator-induced
lung injuries have been reported in several studies [12e19].
Most previous studies indicate that the vasoactive action of
CO2 is dependent on the initial PAP; during basal tone
condition, CO2 is a mild vasoconstrictor, whereas at high
pulmonary vascular resistance, it is a potent vasodilator
[5,7e11,14,18]. The differences in pulmonary vascular tone
may account for the discrepant vasoactive action of CO2.
Our previous data represented the first demonstration of
a pressure-response relationship between the degree of CO2-
induced vasodilatation and the level of PAP. We observed
that the vasodilatory effect of CO2 tends to be more evident
at high PAP. In clinical settings, pulmonary arterial hyper-
tension occurs under different clinical conditions depending
on the associated disease. In our study, we also found that
CO2 is not a specific eliminator to hypoxia and endothelin-1
(ET-1)einduced pulmonary hypertension [20]. Because
pulmonary hypertension secondary to increased pulmonary
blood flow and pulmonary vasoconstriction often coexists
with altered vascular reactivity, there has been considerable
interest in the discrepant vasoactive action of inhaled CO2
under the different conditions of pulmonary hypertension.
It is known that endothelial cells release vasoactive
substances in modulating pulmonary vascular tone. Nitric
oxide (NO) and ET-1 have been shown to be the major endo-
thelium-dependent vasomediators [21e23]. The response of
the pulmonary endothelium to increased flow and hypoxiamay play an important role in the modulation of pulmonary
vessel response to increasing pressure. There is evidence that
NO plays an important role in the modulation of endothelial
stress induced by increased pulmonary blood flow and
hypoxic stimulation [24e27].
In the present study, we attempted to characterize the
effect of inhaled CO2 on pulmonary vascular response under
different conditions of pulmonary hypertension induced by
increased pulmonary blood flow and hypoxic pulmonary
vasoconstriction. We also attempted to clarify the role of
NO in mediating the pulmonary vascular response to
hypercapnia, hypoxia, and increased pulmonary blood flow.
Therefore, the pulmonary vascular responses to CO2 inha-
lation were observed in isolated rat lungs under different
levels of PAP induced by graded perfusion flow speed. The
effects of inhaled CO2 on pulmonary hypertension were
evaluated by comparing vascular tone at normoxic-hyper-
capnia (5% CO2 in air) and vascular tone at hypoxic-hyper-
capnia (5% CO2 in N2) ventilation. Furthermore, to clarify
the modulatory role of NO, we investigated the effect of NO
and ETB (endothelin type B receptor) blockade on hyper-
capnia, hypoxia, and increased blood flow induced changes
in pulmonary vascular tone.
Materials and methods
Animals
Adult male Sprague-Dawley rats weighing 300e350 g were
used. The specific pathogen-free animals were purchased
from the National Animal Center and housed in a tempera-
ture-controlled animal room. The room temperature was
maintained at 22  1C under a 12/12-hour light/dark
regimen. Food and water were available ad libitum. The
use and care of the animals were approved by the Animal
Care and Use Committee of Kaohsiung Medical University.
Isolation and perfusion of rat lungs
The rats were deeply anesthetized with an intraperitoneal
injection of pentobarbital sodium (50 mg/kg). The experi-
mental setup was modified from previous studies [28]. After
tracheotomy, the lungs were artificially ventilated with
room air. Heparin (1 U/g) was administered into the left
ventricle after a midsternal thoracotomy. A total of 10 mL
of blood was collected from the right ventricle and mixed
with 10 mL of Hank’s balanced salt solution (in mM: NaCl
136.9, KCl 5.4, glucose 5.6, KH2PO4 0.4, Na2HPO4 0.3, and
6% albumin and pH was adjusted to 7.35e7.40) and subse-
quently used to perfuse the isolated lungs. Furthermore,
the perfusion medium was gassed with a mixture of 5% CO2
and monitored continuously for pH. During the initial
stabilization period, the pH was adjusted to 7.4  0.05 with
HCl. A cannula was placed in the pulmonary artery through
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placed around the main trunk of the pulmonary artery. A
large catheter was inserted into the left atrium through the
left ventricle and mitral valve and fixed by ligature at the
apex of the heart to divert pulmonary venous outflow into
a reservoir. A third ligature was placed above the arterio-
ventricular junction to prevent perfusate flow into the
ventricles. Perfusion fluid maintained at 37  0.5C was
circulated by use of a roller pump at a flow rate of 10 mL/
min. The PAP and pulmonary venous pressure were
measured with pressure transducers (Gould Instruments,
Cleveland, OH, USA) from a side arm of the inflow and
outflow cannula. The pulmonary venous pressure was set at
2 mmHg by adjusting the height of the venous reservoir.
After an initial hyperinflation to reverse atelectasis, the
lungs were ventilated at 60 breaths/min and tidal volume at
2.5e3 mL. The end-expiratory pressure was set at 2 cmH2O.
The gas tension in the perfusate was measured at the
beginning of each experiment and after changes in ventila-
tory gas mixtures, by collecting perfusion fluid anaerobically
and analyzing immediately using a gas analyzer (Stat Profile
5; Nova Biomedical, MA, USA). There were three criteria for
a satisfactory isolated lung preparation: no leakage at the
site of cannula insertion, no evidence of hematoma or
edema, and an isogravimetric state.
Drug preparation and delivery
N-Nitro-L-arginine methyl ester (L-NAME, NO synthase
blocker) and BQ788 (ETB receptor blocker) were purchased
from Sigma (Sigma Chemical, St. Louis, MO, USA) and were
added to the venous reservoir to give a final concentration
of 400 mM and 1 mM in the perfusate.
Experimental outline
Experiments in isolated perfused lungs were carried out in
two series; and different perfusion rates (13, 18, 25 mL/
min) were used to induce various levels of PAP elevation. In
Experiment Series A, we examined the effect of CO2 on the
flow-associated PAP elevation under normoxic-hypercapnia
ventilation both with (Group A1) and without (Group A2)
endogenous NO. To assess the role of NO in mediating the
pulmonary vascular response to flow challenge and hyper-
capnia, Group A2 was pretreated with L-NAME (400 mM) and
BQ788 (1 mM); and the PAP change was compared among
Groups A1 and A2.
Experiment Series B was carried out to evaluate the
effect of CO2 on the flow-associated PAP elevation under
hypoxic-hypercapnia ventilation with (Group B1) and
without (Group B2) endogenous NO. To clarify the modu-
lation role of NO in response to flow challenge and hypoxic-
hypercapnia, Group B2 were pretreated with L-NAME
(400 mM) and BQ788 (1 mM); and the pulmonary vascular
response was compared between Groups B1 and B2.
Experimental protocol
During the baseline period, lungs were ventilated with room
air under constant perfusion flow (10 mL/min). Subse-
quently, the preparations were randomized into four groups(A1, n Z 8; A2, n Z 8; B1, n Z 8; and B2, n Z 8) and
sequentially challenged by graded increase in perfusion
flow from 10 mL/min, to 13 mL/min, 18 mL/min, and
25 mL/min. In Groups A2 and B2, the isolated lungs were
pretreated with L-NAME 15 minutes before the flow chal-
lenge and 5 minutes later, with BQ788, 10 minutes before
commencing the flow challenge. Following each challenge
of flow alteration, the pH, gas tension in the perfusate, and
PAP were obtained after steady PAP values were observed
over a period of at least 10 minutes. Thereafter the inspired
gas was switched to the following mixture: (1) Groups A1
and A2: normoxic-hypercapnia gas with 5% CO2 in air and (2)
Groups B1 and B2: hypoxic-hypercapnia gas with 5% CO2 in
N2. After 10 minutes of experimental gas inhalation, the
changes of PAP, pH, and the gas tension in the perfusate
were recorded. The inspired gas was then switched back to
room air for 10 minutes before the next challenge of flow
alteration and gas inhalation.
Statistical analysis
Values are expressed as means  standard deviation or
means  standard error of the mean as appropriate.
Statistical evaluation of the differences among and within
groups was performed using the paired Student t test. The p
values less than 0.05 were considered to be statistically
significant.
Results
CO2 on the flow-associated PAP elevation under
normoxic-hypercapnia ventilation with and without
endogenous NO
In Experiment Series A, ventilation with normoxic-hyper-
capnia gas produced a significant increase in PaCO2 (p< 0.01)
and a decrease in pH (p < 0.01) (Table 1). Three challenges
(10e13 mL/min, 18 mL/min, and 25 mL/min) of increased
perfusion flow elevated the PAP by 4.0  1.0 mmHg,
6.5 1.3 mmHg, and 7.6 1.2 mmHg by a significant amount
(p < 0.01) (Table 1, Fig. 1A). Neither inhalation of normoxic-
hypercapnia nor normal room air breathing had a significant
influence on the PAP (Fig. 1A and B).
In Group A2, there was no significant change on basal
PAP with L-NAME and BQ788 pretreatment. In this group, we
observed that the flow-associated PAP elevation was not
affected under endogenous NO inhibition (p > 0.05,
compared with Group A1) (Fig. 3). The increases in PAP
were 4.4  1.1 mmHg, 7.1  0.9 mmHg, and
8.0  0.5 mmHg by three sequential flow alterations
(p < 0.01) (Table 1, Fig. 1A). Neither normoxic-hypercapnia
gas inhalation nor room air breathing changed the PAP
significantly (Fig. 1A and C).
CO2 on the flow-associated PAP elevation under
hypoxic-hypercapnia ventilation with and without
endogenous NO
In Experiment Series B, ventilation with hypoxic-hyper-
capnia gas produced a significant increase in PaCO2
Table 1 pH, PCO2 in the perfusate, and PAP during the different experimental conditions
Treatment: Baseline (10 lpm) 13 lpm Gas inhalation Room air 18 lpm Gas inhalation Room air 25 lpm Gas inhalation Room air
Group A1
PAP 14.4  0.9 18.4  0.9 18.2  0.8 18.2  0.7 24.7  1.4 24.6  1.2 24.8  1.1 32.4  2.1 31.6  2.0 32.0  2.1
PCO2 34.6  1.4 65.2  5.2a 36.4  2.4 68.8  6.6a 37.5  2.8 64.7  6.1a
pH 7.34  0.08 7.20  0.10a 7.35  0.06 7.14  0.09a 7.39  0.08 7.13  0.11a
Group A2
PAP 14.7  1.3 19.0  1.2 19.1  1.4 19.1  1.0 26.2  1.3 26.0  1.4 25.8  1.3 33.8  1.5 33.3  1.7 33.3  1.6
PCO2 38.9  0.6 72.8  6.4a 39.9  0.8 68.7  5.9a 42.1  1.8 72.2  6.6a
pH 7.39  0.06 7.08  0.12a 7.34  0.9 7.19  0.10a 7.43  0.16 7.05  0.15a
Group B1
PAP 15.0  1.0 19.1  1.2 21.1  1.3 20.2  1.2 25.6  1.3 28.7  1.5 27.0  1.2 34.1  1.2 38.2  1.9 35.4  1.8
/18.6  1.2 /25.1  1.2 /33.1  1.5
PCO2 34.6  0.8 68.2  4.9a 39.2  1.3 65.6  5.9a 41.2  1.7 64.2  5.3a
pH 7.34  0.04 7.18  0.09a 7.38  0.05 7.15  0.09a 7.38  0.08 7.14  0.14a
Group B2
PAP 14.6  1.4 18.7  1.4 21.9  1.7 20.7  1.5 26.9  0.9 32.8  1.3 28.9  1.1 36.8  2.1 45.2  1.78 38.5  2.2
/18.6  1.5 /26.9  1.5 /35.8  2.1
PCO2 39.2  0.7 67.8  6.6a 36.2  0.9 63.2  5.9a 34.5  0.4 63.2  6.4a
pH 7.40  0.08 7.11  0.13a 7.35  0.09 7.17  0.11a 7.33  0.07 7.09  0.14a
a Less than 0.01 compared with corresponding values before gas inhalation.
Gas inhalation: Group A1Z 5% CO2 in air; Group A2Z 5% CO2 in air, pretreated with L-NAME + BQ788; Group B1Z 5% CO2 in N2; Group B2Z 5% CO2 in N2, pretreated with L-NAME + BQ788;































Figure 1. (A) Graph representing means  standard error,
PAP at baseline, and during the course of the experiment in
Series A. PAP increased significantly in response to flow alter-
nation (a,bp < 0.01 compared with base). (B) and (C) Values are
means  standard deviation. PAP changes in response to nor-
moxic-hypercapnia gas (5% CO2 in air) following with flow
challenges at various speeds for Groups A1 and A2. Normoxic-
hypercapnia gas (5% CO2 in air) has no influence on PAP.
CO2 Z carbon dioxide; L-NAME Z N-nitro-L-arginine methyl
ester; PAP Z pulmonary arterial pressure; RA Z room air.
340 I.-C. Chuang et al.(p < 0.01) and a decrease in pH (p < 0.01) (Table 1). In
Group B1, the perfusion flow at rates of 13 mL/min, 18 mL/
min, and 25 mL/min elevated the PAP by 4.1  0.7 mmHg,
4.7  1.0 mmHg, and 7.1  0.9 mmHg, respectively
(p < 0.01) (Table 1, Fig. 2A). Hypoxic-hypercapnia venti-
lation (5% CO2 in N2) evoked a biphasic response with
transient hypoxic vasoconstriction. PAP was initially
increased by 2.0  0.4 mmHg, 3.1  0.7 mmHg, and
4.1  0.9 mmHg (p < 0.05). However, after 4e6 minutes of
gas inhalation, PAP began to gradually drop; after 10minutes of gas inhalation, PAP had decreased by
2.4  0.5 mmHg, 3.6  0.6 mmHg, and 5.2  0.9 mmHg
(p < 0.01) (Table 1, Fig. 2A and B). The PAP rebounded by
1.5  0.3 mmHg, 2.0  0.3 mmHg, and 2.4  0.4 mmHg,
respectively, when the inhaled gas was changed to room air
(Fig. 2A). In Group B2, inhibition of NO synthesis with L-
NAME and BQ788 also evoked a biphasic response with
a transient hypoxic vasoconstriction. In this group, the PAP
was elevated by 4.1  0.7 mmHg, 5.4  0.9 mmHg, and
8.0  2.0 mmHg during three challenges of flow alteration
(p < 0.01) (Table 1, Fig. 2A). In response to hypoxic-
hypercapnia gas (5% CO2 þ N2), PAP was initially increased
by 3.3  0.6 mmHg, 5.9  0.9 mmHg, and 8.3  1.7 mmHg
(p < 0.01). At 4e6 minutes of gas inhalation, PAP began to
gradually drop; at 10 minutes of gas inhalation, PAP had
decreased by 3.4  0.8 mmHg, 5.9  1.0 mmHg, and
9.4  1.6 mmHg (p < 0.01) (Table 1, Fig. 2A and C). Again,
room air inhalation reversed the PAP by 2.2  0.7 mmHg,
2.0  0.5 mmHg, and 2.7  0.4 mmHg (Fig. 2A). In this
series of experiments, pretreatment with L-NAME and
BQ788 eliminated the endogenous NO, while greatly
potentiating the pulmonary vasoconstriction response to
hypoxia, but did not eliminate the vasodilatory effect of
CO2 (Fig. 2C).Discussion
In the present study, we demonstrated that CO2 provides
a compensatory mechanism to reverse the PAP when
vascular tone is raised by hypoxia, but not by alternation of
perfusion flow (Figs. 1A and 2A). Pretreatment with L-NAME
and BQ788 significantly potentiates hypoxic pulmonary
vasoconstriction (Fig. 2A). However, the pulmonary vaso-
dilatory effects of CO2 are essentially not affected by L-
NAME or BQ788 (Fig. 2D), suggesting that NO is not involved
in the hypercapnic vasodilatation.
There is strong evidence that pulmonary vessels
constrict during hypoxia, hypercapnia, and acidemia. High
CO2 tension with elevated hydrogen ion concentration in
the blood increases the extracellular Ca2þ influx, which is
thought to be the main cause of vasoconstriction in the
pulmonary circulation. The early works of Duke et al. [29]
and Shaw and Barer [8] showed that CO2 usually causes
weak vasoconstriction under normal vascular tone. Addition
of acid also causes vasoconstriction, whereas alkali
administration causes vasodilation. However, CO2 also plays
a vasodilator role under the condition of high vascular tone.
Subsequent studies have reported that respiratory acidosis
tends to attenuate the suppressor response to hypoxia and
vasoconstrictors, whereas respiratory alkalosis exerts the
opposite effect [9,10]. These findings suggest that an
increase in hydrogen ion concentration alone causes
pulmonary vasoconstriction and that an increase in CO2
tension in the blood could attenuate the vasomotor
response to hypoxia or vasoconstrictors in spite of the
hydrogen ion concentration. These findings are consistent
with those of Viles and Shepherd [7], who showed CO2
acted as a pulmonary vasodilator, independent of hydrogen
ion concentration. In this connection, our previous study
also confirmed that the vasodilatory effect of CO2 is pH
independent. In the experiment, under ET-1einduced
Figure 2. (A) Graph representingmeans standard error, PAP
at baseline, and during the course of the experiment in Series B.
PAP increased significantly in response to speed alternation
(a,bp < 0.01 compared with base). In both groups, hypoxic-
hypercapnia gas challenge (5% CO2 in N2) evoked a biphasic
response with a transient hypoxic vasoconstriction [first phase,
Gas(1)] followed by a CO2 vasodilatation [second phase, Gas(2)].
(B) and (C) PAP changes in response to hypoxic-hypercapnia gas
Effect of inhaled CO2 on pulmonary hypertension 341pulmonary hypertension, we infused acetic acid to alter the
pH value close to the value produced by 5% CO2 inhalation.
The infused acetic acid slightly elevated the PAP while
decreasing the pH [20].
The action of CO2 on vascular tone was described to be
a local action because it was present after autonomic
blockade in isolated perfused lungs and was not eliminated
in intact animals by vagotomy or atropine [11]. There has
been considerable interest in the role of NO in mediating
hypercapnic vasodilatation. In the present study, blocking
endogenous NO with L-NAME and BQ788 did not eliminate
the vasodilatory response to hypercapnia, but enhanced
hypoxic pulmonary vasoconstriction. NO seems to specifi-
cally modulate hypoxic pulmonary vasoconstriction while
not being involved in CO2-induced vasodilation. Several
studies have pointed out that an increase in NO production
during acute or chronic hypoxia tends to blunt the vaso-
constrictory effect induced by hypoxia [11,30e33]. In the
present data, in Group B1 we observed a biphasic response
of transient hypoxic vasoconstriction followed by CO2-
induced vasodilatation in response to hypoxic-hypercapnia
(Fig. 2A and B). In Group B2, inhibition of endogenous NO
tended to potentiate the pulmonary vasoconstriction
response to hypoxia, but did not eliminate the vasodilatory
effect of CO2. In both the B1 and B2 groups, this latter
pulmonary vasodilatation could be aborted with pure N2
inhalation (data not shown). These findings suggest that
acute hypoxia causes pulmonary vasoconstriction, but
coexistent hypercapnia inhibits this effect. Comparing the
percentages of CO2-induced vasodilatation in both groups,
the vasodilatory effect of CO2 was not affected by inhibi-
tion of endogenous NO (Fig. 2D). This suggests that NO is
significantly involved in hypoxic vasoconstriction, whereas
not contributing to hypercapnic ventilation in the face of
hypoxic pulmonary hypertension. In contrast to our finding,
Yamaguchi et al. [34] documented that hypercapnic
acidosis elevated vascular tone and perfusate nitrite/
nitrate in an isolated lung model. Other studies have also
reported that hypercapnia acidosis is associated with the
upregulation of nitric oxide synthase-mediated NO depen-
dent effects at the vascular and molecular levels [35,36].
Although our results differ from previous studies, it appears
that acidification may stimulate unidentified mechanisms in
the pretranscriptional phase of endothelial nitric oxide
synthase [37,38].
Study evidence suggests that normal pulmonary vascular
tone is regulated by vasoactive substances that are
produced locally by the vascular endothelium. The
phenomenon of enhanced basal NO production also occurs
in certain types of pulmonary hypertension that is an(5% CO2 in N2) following with flow challenges at various speeds
for Groups B1 and B2. (Values are means  standard deviation.
cp < 0.05; bp < 0.01 hypoxic vasoconstriction compared with
previous course of gas challenge. ap < 0.01 CO2 vasodilatation
vs. previous course of gas challenge). (D) Values are
means  standard deviation. Percent relaxation in response to
CO2 showed no significant difference between Groups B1 and B2.
The vasodilatation effect of CO2 was not affected by L-NAME and
BQ788. CO2 Z carbon dioxide; L-NAME Z N-nitro-L-arginine
methyl ester; PAPZ pulmonary arterial pressure; RAZ room air.
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[24,26]. However, the response of the pulmonary vascula-
ture to increase in blood flow appears to be very contra-
dictory. Some reports indicate that increased blood flow
produces endothelial dysfunction with loss of endothelial
dependent vasodilatation [27e39]. In the present study, we
did not observe the phenomenon of flow-associated NO
enhancement in comparing the flow-induced PAP elevation
among the groups with and without inhibition of endoge-
nous NO (Fig. 3). Furthermore, from the observation in the
study of Series B, the hypoxic vasoconstriction response
was potentiated with inhibition of endogenous NO. If NO
formation was deprived in flow-induced pulmonary hyper-
tension, endogenous NO inhibition should not cause
a higher magnitude of pressure rise in response to hypoxia
stimulation.
As mentioned in the literature review, there is no
significant difference in pulmonary vascular resistance in
response to graded CO2 or varying concentrations of CO2
[8,9,34,40]. In the present study, we simply used a concen-
tration of 5% CO2, which produced a degree of hypercapnia
acidosis similar to that commonly observed when using
protective ventilatory strategies in clinical illness. Reports
to date of the vasoactive action of CO2 have concentrated
on its vasodilatory and beneficial effects. Although we know
that discrepant vasoactive action of CO2 may arise from
differences in pulmonary vascular tone, the concept of
a pressure-response relationship between the degree of
CO2-induced vasodilatation and the level of PAP still needs
to be elucidated. Therefore, our study was in large part
designed to identify whether the vasodilator effect of CO2
on the pulmonary circulation is dependent on the level of
PAP and to assess the effect of CO2 on pulmonary vascular
tone under various conditions. In clinical situations, hyper-
capnia, hypoxia, and increased blood flow usually coexist in
pulmonary hypertension. There has been considerable
interest in the effect of CO2 on hypoxic and flow alter-
ationeinduced pulmonary hypertension. However, in the
present study, we observed that CO2 reversed the PAP only
when induced by hypoxia stimulation, but not when induced
by alteration of perfusion flow. Pulmonary hypertension
secondary to increased pulmonary blood flow and hypoxicFigure 3. Graph representing means  standard deviation
increase in pulmonary arterial pressure at varying perfusion
flow rate (13 mL/min, 18 mL/min, and 25 mL/min) in all study
groups. There are no significant differences between groups in
response to each challenge of flow alternation (p > 0.05).
Group A1: 5% carbon dioxide (CO2) in air; Group A2: 5% CO2 in
air, pretreated with N-nitro-L-arginine methyl ester þ BQ788;
Group B1: 5% CO2 in N2; Group B2: 5% CO2 in N2, pretreated with
N-nitro-L-arginine methyl ester þ BQ788. PAP Z pulmonary
arterial pressure.pulmonary vasoconstriction often coexists with altered
vascular reactivity. The discrepant results may arise from
the specific vasodilatory action of CO2. The vasoactive
action of CO2 did not affect the flow-associated pulmonary
hypertension because the pulmonary vessels act as
a distensible tube that enlarges with increasing flow,
leading to increased PAP.
The major findings of the present study are encouraging
in that elevated CO2 tension in arterial blood might have
a protective effect and this could have important implica-
tions for the clinical management of mechanical ventilation
in intensive care settings. In conclusion, there are several
aspects of our present study that provide evidence that (1)
inhaled CO2 reversed pulmonary hypertension induced by
hypoxia but not by flow alteration; (2) the vasodilatory
effects of CO2 at different pressure levels vary in accor-
dance with the levels of PAPdthe dilatory effect tends to
be more evident at higher PAP; and (3) endogenous NO
attenuates hypoxic pulmonary vasoconstriction but does
not augment the CO2-induced vasodilatation.Acknowledgments
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